September 27, 2022
BioPharm America 2022 September 28 & 29
Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc., will be attending the BioPharm America 2022 conference in Boston on September...
Read More
September 20, 2022
RESI Boston 2022 Partnering Platform
Lu Alleruzzo, Co-Founder & CEO, at Immunophotonics, Inc. will be attending the RESI Boston 2022 Partnering Platform, September 21st &...
Read More
September 20, 2022
SACHS Associates 22nd Annual Biotech in Europe Forum
Dr. Theresa Visarius, Immunophotonics Vice President Business Development and Managing Director of the Swiss subsidiary IPS Biopharma AG will be...
Read More
September 10, 2022
Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Conference
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the Cardiovascular and Interventional Radiology Society of Europe (CIRSE)...
Read More
September 9, 2022
European Society of Medical Oncology (ESMO) Congress
Lu Alleruzzo, Co-Founder & CEO at Immunophotonics, Inc. attended the European Society of Medical Oncology (ESMO) Congress in Paris, France...
Read More
August 31, 2022
Immunophotonics Announces Appointment of New Chief Medical Officer and Chief Scientific Officer
Immunophotonics, Inc. is thrilled to announce the addition of Dr. Edwina Baskin-Bey in the role of Chief Medical Office (CMO)...
Read More
July 7, 2022
Tomas Hode, Wei R. Chen, Siu Kit “Samuel” Lam T Cell Paper Publication
Immunophotonics would like to congratulate Ashley Hoover and Kaili Liu lead authors from the University of Oklahoma and to the...
Read More
June 13, 2022
Swiss MedTech Day June 14, 2022
Dr. Theresa Visarius, VP of Business Development at Immunophotonics, Inc. will be attending 2022 Swiss MedTech Day on Tuesday, June...
Read More
June 13, 2022
Society of Interventional Radiology Annual Scientific Meeting (SIR), June 11-16, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. will be attending the Society of Interventional Radiology Annual Scientific...
Read More
May 11, 2022
Immunophotonics Announces First Patient Dosed in Phase 2a Clinical Trial of IP-001 in advanced solid tumor indications
Immunophotonics announced that the first patient has been dosed in the phase 2a portion of its Swiss clinical trial for...
Read More